Can Foreign Companies Own 100% of a Pharma Subsidiary in China?

1. The Regulatory Landscape: From Joint Venture Mandates to Full Ownership

For decades, foreign pharmaceutical companies seeking to manufacture drugs in China were required to establish joint ventures (JVs) with Chinese partners. This mandatory JV structure was codified in the Catalogue of Industries for Guiding Foreign Investment (the “Negative List”), which classified pharmaceutical manufacturing as a “restricted” industry where foreign ownership was capped and a JV structure was required. The restriction was rooted in the belief that foreign control over drug manufacturing could compromise national health security and that technology transfer through JVs would benefit the domestic industry.

The turning point came with the 2021 edition of the Negative List (effective January 1, 2022), which removed the JV requirement for foreign investment in pharmaceutical manufacturing. This landmark change opened the door for foreign pharma companies to establish wholly foreign-owned enterprises (WFOEs) for drug production in China for the first time since the industry was opened to foreign investment in the 1990s. The change applied broadly to the manufacture of chemical drugs, biological products, and active pharmaceutical ingredients.

This deregulation was part of China’s broader strategy to integrate its pharmaceutical sector with global standards, attract advanced R&D capabilities, and address the growing domestic demand for innovative medicines. The policy shift aligned with China’s 14th Five-Year Plan for the pharmaceutical industry, which emphasized innovation, quality improvement, and international cooperation. China’s rapidly aging population and rising chronic disease burden created urgency for faster access to innovative drugs, which foreign companies could supply more readily through wholly-owned operations.

It is important to note that while the JV requirement was removed, foreign pharma companies still face certain restrictions and must comply with sector-specific regulations, including those governing drug registration, GMP certification, pricing, and distribution. The removal of the JV requirement removed one barrier but did not eliminate the broader regulatory complexity of operating in China’s pharmaceutical sector.

2. What Types of Pharma Subsidiaries Can Be 100% Foreign-Owned?

Under current regulations, the following types of pharmaceutical operations are generally open to 100% foreign ownership through a WFOE structure:

2.1 Drug Manufacturing

Foreign companies can establish WFOEs for the manufacture of chemical drugs, biological products, and active pharmaceutical ingredients (APIs) without requiring a Chinese joint venture partner. This applies to both innovative drugs and generics, subject to standard Good Manufacturing Practice (GMP) certification requirements. The manufacturing WFOE must obtain a Drug Manufacturing License from the provincial NMPA authority and pass GMP certification inspections before commencing production.

2.2 Drug R&D and Clinical Trial Operations

Contract research organizations (CROs) and R&D centers conducting pharmaceutical development can operate as 100% foreign-owned entities. This includes conducting clinical trials as sponsors, managing trial sites, and performing laboratory research. The Center for Drug Evaluation (CDE) accepts trial applications from foreign-owned entities without discrimination. Many of the world’s largest CROs, including IQVIA and Covance, operate Chinese subsidiaries as WFOEs.

2.3 Pharmaceutical Distribution and Wholesale

Wholly foreign-owned pharmaceutical trading companies are permitted, provided they obtain the necessary Drug Distribution License from provincial-level drug regulators. Foreign-owned distributors must meet the same storage, cold-chain, and traceability requirements as domestic firms under the Good Supply Practice (GSP) standards. Several major international pharmaceutical distributors, including Zuellig Pharma, operate WFOE distribution entities in China.

2.4 Medical Device Manufacturing

The medical device sector has been open to 100% foreign ownership since earlier regulatory reforms. Foreign companies can manufacture Class I, II, and III medical devices through WFOEs, subject to NMPA registration requirements. This includes both in-vitro diagnostics and medical equipment manufacturing.

3. Areas Where Restrictions Remain

Despite the general liberalization, several important restrictions remain in place for foreign ownership in China’s pharmaceutical sector. These restrictions reflect ongoing concerns about national security, public health, and the protection of traditional Chinese medicine heritage.

3.1 Traditional Chinese Medicine (TCM) Decoction Pieces

The Negative List continues to restrict foreign investment in the processing of TCM decoction pieces. This subsector requires a joint venture with a Chinese partner and remains classified as “restricted.” Foreign companies interested in TCM should consider licensing arrangements, technology cooperation, or strategic partnerships rather than full ownership. The restriction reflects China’s policy of protecting its traditional medicine heritage and maintaining domestic control over TCM production.

3.2 Vaccines for Human Use

While general drug manufacturing is open, certain vaccine production activities remain subject to additional restrictions. Foreign majority ownership in vaccine manufacturing facilities may require special approvals from the Ministry of Commerce (MOFCOM) and the NMPA. Blood products and narcotic/psychotropic drugs are also subject to special controls under separate regulations. These restrictions were tightened in response to the 2018 vaccine scandal and subsequent regulatory reforms that emphasized domestic production capacity for essential vaccines.

3.3 Gene Therapy and Cell Therapy (Special Review)

Although not explicitly restricted under the Negative List, investments in gene therapy and cell therapy involving human genetic resources are subject to strict oversight under the Regulations on Human Genetic Resources Management. Foreign companies must obtain approval from the Ministry of Science and Technology (MOST) for any activities involving the collection, storage, or export of human genetic materials. These approvals involve a security review process that adds 6-12 months to project timelines. The regulation was significantly tightened in 2019 with amendments that expanded the scope of regulated activities and increased penalties for non-compliance.

3.4 Medical Institutions

Foreign-owned hospitals and clinics remain subject to ownership caps and geographic restrictions under separate regulations. Foreign pharma companies cannot operate wholly-owned hospital chains without a Chinese partner in most regions. The Free Trade Zones (FTZs) have pilot programs allowing wholly foreign-owned hospitals in certain locations, including Shanghai FTZ and Hainan Boao Lecheng pilot zone, but this remains the exception rather than the rule.

4. The WFOE Establishment Process for Pharma Companies

Setting up a wholly foreign-owned pharmaceutical subsidiary in China involves several key steps, each with its own timeline and regulatory requirements. The total process from initial planning to operational readiness typically takes 8-18 months.

4.1 Business Scope Determination

The WFOE’s business scope must be precisely defined in the company’s articles of association and registered with the Administration for Market Regulation (AMR). For pharma companies, the scope must specify the exact categories of drugs to be manufactured, which determines subsequent licensing requirements. Overly broad scopes may be rejected by the AMR, while overly narrow ones may require future amendments that are time-consuming and expensive. Foreign companies should work with experienced registration agents to craft an appropriate business scope that allows for future expansion.

4.2 Company Registration

The registration process involves name pre-approval, submission of incorporation documents, registration with the AMR, and obtaining a unified social credit code. This typically takes 3-4 weeks for a straightforward WFOE, though pharma-specific approvals add time. The company must also register with the tax bureau, customs authority (for import/export), and the foreign exchange administration (SAFE).

4.3 Drug Manufacturing License

Before commencing production, the WFOE must obtain a Drug Manufacturing License from the provincial-level NMPA authority. The application requires submission of facility design documents, GMP compliance plans, key personnel qualifications, and quality management system documentation. The review process includes a facility inspection and typically takes 4-6 months. The license is specific to the types of drugs listed in the application and must be amended if the company wishes to manufacture new drug categories.

4.4 GMP Certification

All drug manufacturing facilities must pass GMP certification inspections conducted by the NMPA or provincial authorities. The GMP standards in China were significantly revised in 2019 to align more closely with international standards (ICH Q7, PIC/S guidelines). Foreign-owned facilities are subject to the same standards as domestic manufacturers, with no additional requirements based on ownership structure. However, foreign companies should ensure that their global GMP documentation is adapted to Chinese format requirements, as the NMPA has specific documentation standards that differ from FDA or EMA formats.

4.5 Drug Registration

Each drug product manufactured at the WFOE must be registered with the NMPA through the CDE. The registration pathway depends on whether the drug is a Class 1 innovative drug (global new chemical entity), a Class 2 improved formulation, or a Class 3-6 generic. The registration timeline ranges from 12-36 months depending on the drug class and priority status. Innovative drugs benefit from priority review pathways that can reduce the timeline to 12-18 months.

5. Practical Considerations for Foreign Pharma WFOEs

5.1 Minimum Capital Requirements

China abolished minimum registered capital requirements for most industries in 2014, and pharma manufacturing WFOEs are not subject to statutory minimums. However, practical considerations dictate that the registered capital should be sufficient to cover facility construction, equipment procurement, working capital, and at least 12 months of operations. For a standard pharmaceutical manufacturing WFOE, capital typically ranges from USD 5-20 million depending on the scale and complexity of operations. The capital must be contributed within the timeframe specified in the company’s articles of association, typically 2-5 years.

5.2 Land Use and Facility Construction

Pharmaceutical manufacturing requires industrial land use rights, which are typically leased from local government authorities for 50-year terms. Foreign-owned entities have the same land-use rights as domestic companies. Facility construction must comply with local building codes, environmental impact assessment (EIA) requirements, and specialized pharmaceutical facility standards including cleanroom classifications, HVAC specifications, and waste treatment systems. The EIA process is particularly important for pharma facilities and can take 3-6 months. Foreign companies should budget adequately for the EIA and engage experienced environmental consultants.

5.3 Tax Considerations

Pharmaceutical WFOEs are subject to the standard Corporate Income Tax (CIT) rate of 25%. However, several preferential rates may apply to qualifying companies. The High and New Technology Enterprise (HNTE) status reduces CIT to 15% for qualifying companies engaged in innovative drug R&D. Qualification requires a minimum of 3% of revenue in R&D spending, at least 30% of employees with associate degrees or higher, and a valid IP portfolio. The Western Region Development Policy provides a reduced 15% CIT rate for companies established in qualifying western provinces through 2030. Free Trade Zones such as Shanghai, Hainan, and Guangdong offer additional tax holidays, rent subsidies, and streamlined approval processes that can significantly reduce the overall cost of establishment.

5.4 Intellectual Property Protection

IP protection is a critical consideration for pharma WFOEs. Key measures include the patent linkage system (effective since 2021) that links drug approval to patent status during the ANDA review process, patent term extension (PTE) of up to 5 years for new drug patents compensating for regulatory review delays, data protection period of 6 years for innovative drugs and 3 years for new indications, and trade secret protection under the Anti-Unfair Competition Law with enhanced enforcement since 2019 amendments. Foreign companies should register all relevant patents and trademarks in China before establishing a WFOE, as China operates on a “first-to-file” rather than “first-to-use” IP system.

6. Industry Trends and Outlook for 2026-2027

The trend toward liberalization of foreign investment in China’s pharmaceutical sector is expected to continue. Key developments include the potential further Negative List relaxation in the 2026-2027 revision cycle, driven by WTO commitments and bilateral investment treaty negotiations. The Hainan Boao Lecheng pilot zone and selected FTZs are testing broader foreign ownership frameworks, including wholly foreign-owned medical institutions. China’s NMPA continues to streamline approval pathways for innovative drugs, with breakthrough therapy designations and priority review reducing approval times. The national Volume-Based Procurement (VBP) program affects market dynamics for generic drugs, making WFOE-based local manufacturing more attractive for cost optimization. Several foreign firms have established WFOEs specifically to qualify for VBP participation under local production rules.

7. Common Pitfalls and How to Avoid Them

Foreign pharma companies should be aware of several common pitfalls when establishing a WFOE in China. Underestimating approval timelines is a frequent mistake many foreign companies assume that because the JV requirement has been removed, setting up a pharma WFOE will be quick. In reality, obtaining the Drug Manufacturing License and GMP certification can take 6-12 months. Ignoring provincial variations in policy implementation is another risk, as some provinces actively welcome pharma WFOEs with fast-track approvals and incentives, while others lack experience processing foreign pharma applications. Inadequate due diligence on commercial partners, including verification of their Drug Distribution License and GSP compliance history, is another common issue. Finally, overlooking Human Genetic Resource Management (HRML) requirements for any clinical trials or biomarker testing conducted in China can cause significant delays and regulatory exposure.

8. Frequently Asked Questions

9. Conclusion

The removal of the joint venture requirement for pharmaceutical manufacturing in China represents a significant opportunity for foreign pharmaceutical companies seeking to establish a direct presence in the world’s second-largest pharmaceutical market. The ability to own 100% of a manufacturing subsidiary provides greater operational control, better IP protection, and more flexibility in global supply chain integration. However, the liberalization is not absolute. Foreign pharma companies must navigate remaining restrictions in TCM processing, certain vaccine types, and human genetic resource management. The establishment process remains complex, requiring coordination across multiple regulatory agencies and careful attention to provincial variations in implementation. For most foreign pharmaceutical companies, the WFOE structure is now the preferred market entry vehicle for drug manufacturing in China.